Ophthalmic Business News

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Michelle Senchyna, PhD, of Aerie Pharmaceuticals, provides an update on the company’s ongoing projects.

Salvat Laboratories has submitted a new drug application to the FDA for clobetasol nanoemulsion to treat inflammation and pain after ocular surgery.

Eyenuk has secured $26 million in a Series A financing round, bringing the company’s total funding to more than $43 million.

In this episode, I share my review of the hot topics from the AAO 2022 annual meeting and share my thoughts on the new data shared about drug trials and treatments.

Genentech is voluntarily recalling the Susvimo implant and insertion tool for the treatment of wet age-related macular degeneration in the U.S., according to a company statement.

Wow. It’s been an interesting couple of weeks on the industry side of eye care, eh?

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest ophthalmic industry news and interview Steve Schallhorn, MD, Julie Schallhorn, MD, MS, Craig S. Schallhorn, MD, Erin Schallhorn Powers and Eileen Schallhorn.

Oh my. We were just getting over Alcon jettisoning the entire Kala sales force after acquiring Inveltys and Eysuvis, and now this: Allergan just let go of a massive number of eye care sales reps.

Like their patients, physicians often become more concerned about long-term care coverage as they age.

The FDA granted fast track designation to MCO-010 from Nanoscope Therapeutics for the treatment of retinitis pigmentosa.